The article reports on the efforts of the Food and Drug Administration to strengthen its Prescription Drug User Fee program which has to be reauthorized by October 1, 2007 in the U.S. The agency officials, patient disease groups and the pharmaceutical firms praise its success in accelerating new drugs to the market.